Search clinical trials for: Deferoxamine Mesylate

Total 1696 results

Central European Cooperative Oncology Group

Completed

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Croatia, Bosnia and Herzegovina, Romania, Slovakia, Bulgaria, Czech Republic, Austria, Lithuania, Serbia, Slovenia
Cttq
Ruijin Hospital

Unknown

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Novartis Pharmaceuticals

Completed

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Gastrointestinal Stromal Tumors
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Novartis

Completed

Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen

Seasonal Allergic Rhinitis

United Kingdom
Hansoh BioMedical R&D Company

Not yet recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
Zhihong LU

Not yet recruiting

Dose of Remimazolam in Children for Intubation (DRIP)

Anesthesia
Southern California College of Optometry at Marshall...

Completed

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Early Intracordal Hyaluronic Acid Injection During Spontaneous Reinnervation for Unilateral Recurrent Laryngeal Nerve Paralysis

Paralysis, Unilateral, Vocal Cord

Taiwan
M.D. Anderson Cancer Center

Active, not recruiting

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Breast Inflammatory Carcinoma | Recurrent Breast Inflammatory Carcinoma | Stage IV Breast Inflammatory Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

United States
Wuhan Union Hospital, China

Not yet recruiting

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Non Small Cell Lung Cancer
Beijing Sanbo Brain Hospital

Recruiting

Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults

Recurrent Atypical/Malignant Meningioma

China
Samsung Medical Center

Active, not recruiting

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Advanced, Refractory Cancer

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Subjects With Impaired Renal Function and Healthy Subjects
Dana-Farber Cancer Institute
Genentech, Inc.; Eisai Inc.

Terminated

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

United States
Kent Robertson

Completed

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas (0908-09)

Neurofibromatosis | Neurofibromas

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Indiana University

Completed

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis

United States
Novartis Pharmaceuticals

Completed

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors

Italy
University of Michigan Rogel Cancer Center

Completed

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

Small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck

Carcinoma, Adenoid Cystic | Cancer of the Head and Neck

France
Hospices Civils de Lyon

Unknown

Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.

Acute Lymphocytic Leukemia

France
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia

United States
Arog Pharmaceuticals, Inc.

Terminated

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Glioma

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions

Healthy

Canada
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications | Targetd Therapy

China
The First Affiliated Hospital of Soochow University

Recruiting

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

CML, Chronic Phase; TKI

China
Asan Medical Center

Active, not recruiting

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

Gastrointestinal Stromal Tumors

Korea, Republic of
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
First Affiliated Hospital of Harbin Medical University

Terminated

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Adenoid Cystic Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study (RASS)

Sarcoma | Head and Neck Cancer | Soft Tissue and Bone Tumor

China
Centre Oscar Lambret
Novartis; National Cancer Institute, France

Terminated

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

Melanoma

France
Novartis Pharmaceuticals

No longer available

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination (MACS2226)

Gastrointestinal Stromal Tumor

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Italy
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche

Unknown

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Systemic Sclerosis

Italy
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
Peking University People's Hospital

Completed

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Efficacy | Toxicity, Drug

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma (Spark-AL003)

Lung Carcinoma

China
Sun Yat-sen University

Unknown

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Non-small Cell Lung Cancer

China
University of Oxford
Johns Hopkins Bloomberg School of Public Health; University of Otago; Patan Academy...

Completed

PCV10 Immunogenicity Study Nepal 2015

Streptococcus Pneumoniae

United Kingdom
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (HCC)

Hepatocellular Carcinoma

China

Search clinical trials for: Deferoxamine Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations